Condition: Aortic Stenosis · Sponsor: Shanghai MicroPort CardioFlow Medtech Co., Ltd.
This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness of Microport™ CardioFlow VitaFlow™ II Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.
This description comes directly from the study's public registry record.
Bi Jie · (86)(21)38954600 · jbi@microport.com
Zhujun Cai, PhD · (86)(21)38954600 · zjcai@microport.com
Always discuss trial participation with your own doctor first.
| Fuwai Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Zhongshan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04414878